Perrigo announces FDA approval for generic Prilosec

ALLEGAN, Mich. Perrigo on Tuesday added a private-label version of Johnson & Johnson’s Pepcid Complete to its gastrointestinal portfolio, which will include the launch of a store brand Prilosec OTC in the next quarter, with the announcement that the Food and Drug Administration approved its application for over-the-counter famotidine 10 mg, calcium carbonate 800 mg and magnesium hydroxide 165 mg, chewable tablets.

Annual retail sales for Pepcid Complete chewable tablets are estimated to be approximately $95 million, Perrigo reported.

“This final approval reflects our continuing investment in new products,” Perrigo’s Chairman and chief executive officer Joseph Papa stated. “As always, Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders.”